Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 8, 2025

CONFIRM anti-CD3 (2GV6) Rabbit Monoclonal Primary Antibody

RRID:AB_2335978
Type: Antibody

Proper Citation

(Ventana Medical Systems Cat# 790-4341, RRID:AB_2335978)

Antibody Information

URL: http://antibodyregistry.org/AB_2335978

Proper Citation: (Ventana Medical Systems Cat# 790-4341, RRID:AB_2335978)

Target Antigen: CD3

Host Organism: rabbit

Clonality: monoclonal

Comments: Used By NYUIHC-743
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: CONFIRM anti-CD3 (2GV6) Rabbit Monoclonal Primary Antibody

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: 2GV6

Antibody ID: AB_2335978

Vendor: Ventana Medical Systems

Catalog Number: 790-4341

Alternative Catalog Numbers: 05278422001

Record Creation Time: 20231110T041942+0000

Record Last Update: 20241114T230100+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for CONFIRM anti-CD3 (2GV6) Rabbit Monoclonal Primary Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Donati B, et al. (2024) Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer immunology research, 12(1), 120.

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

Radtke AJ, et al. (2024) Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients. Cancer cell, 42(3), 444.

De Sanctis F, et al. (2024) Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Immunity, 57(6), 1378.

Zhang C, et al. (2024) Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC:

Phase 2 trial interim results (NEOTIDE/CTONG2104). Cell reports. Medicine, 5(7), 101615.

Hansen AR, et al. (2024) Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(24), 5540.

Campbell MJ, et al. (2024) Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell reports. Medicine, 5(11), 101799.

Pouyabahar D, et al. (2023) A rat liver cell atlas reveals intrahepatic myeloid heterogeneity. iScience, 26(11), 108213.

Tabata M, et al. (2023) Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma. Cell reports, 42(7), 112736.

Chiu D, et al. (2023) A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma. Cancer research communications, 3(1), 130.

van Hijfte L, et al. (2023) Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling data. iScience, 26(1), 105760.

Yanagawa J, et al. (2023) Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma. Cancer research, 83(19), 3305.

Egan H, et al. (2023) Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment. Cell reports, 42(5), 112475.

Yousuf S, et al. (2023) Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer. Gastroenterology, 165(4), 891.

Basolo A, et al. (2023) Autopsy Study of Testicles in COVID-19: Upregulation of Immune-Related Genes and Downregulation of Testis-Specific Genes. The Journal of clinical endocrinology and metabolism, 108(4), 950.

Nicolas AM, et al. (2022) Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer cell, 40(2), 168.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(23), 5190.

Burkard T, et al. (2022) Differential expression of CD8 defines phenotypically distinct cytotoxic T cells in cancer and multiple sclerosis. Clinical and translational medicine, 12(12), e1068.

Poma AM, et al. (2022) Suppression of Pituitary Hormone Genes in Subjects Who Died From COVID-19 Independently of Virus Detection in the Gland. The Journal of clinical

endocrinology and metabolism, 107(8), 2243.